help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ringel, M. D.
Right arrow Articles by Ladenson, P. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ringel, M. D.
Right arrow Articles by Ladenson, P. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*LEVOTHYROXINE
Medline Plus Health Information
*Thyroid Cancer

Journal of Clinical Endocrinology & Metabolism, Vol 81, 1724-1725, Copyright © 1996 by Endocrine Society

ARTICLES

Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism

MD Ringel and PW Ladenson
Johns Hopkins Thyroid Tumor Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.

The diagnostic and therapeutic use of radioactive iodine in patients with thyroid cancer requires a sufficient serum concentration of thyrotropin (TSH) for efficient thyroid tissue uptake of radioiodine. Recombinant human TSH (rhTSH) is a promising new agent, which appears to facilitate radioiodine scanning with similar efficacy to thyroid hormone withdrawal without the immunologic side-effects of bovine TSH (bTSH) administration. Patients with thyroid cancer and concomitant secondary hypothyroidism are particularly difficult to treat because of their inability to elevate endogenous TSH and the limitations of bTSH administration. We describe a patient with metastatic thyroid carcinoma and secondary hypothyroidism with metastases visible only after administration of rhTSH previously unappreciated on thyroid hormone withdrawal scans. This patient exemplifies the usefulness of rhTSH administration before radioactive iodine for this group of patients.


This article has been cited by other articles:


Home page
 J. Nucl. Med. Technol.Home page
V. Muller, K. H. Bohuslavizki, S. Klutmann, and M. Clausen
Value of Recombinant Human Thyrotropin in High-Dose Radioiodine Therapy: A Case Report
J. Nucl. Med. Technol., December 1, 2002; 30(4): 185 - 188.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Luster, M. Lassmann, H. Haenscheid, U. Michalowski, C. Incerti, and C. Reiners
Use of Recombinant Human Thyrotropin before Radioiodine Therapy in Patients with Advanced Differentiated Thyroid Carcinoma
J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3640 - 3645.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Rotman-Pikielny, J. C. Reynolds, W. C. Barker, P. M. Yen, M. C. Skarulis, and N. J. Sarlis
Recombinant Human Thyrotropin for the Diagnosis and Treatment of a Highly Functional Metastatic Struma Ovarii
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 237 - 244.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. E. Vargas, H. Uy, C. Bazan, T. A. Guise, and J. M. Bruder
Hemiplegia after Thyrotropin Alfa in a Hypothyroid Patient with Thyroid Carcinoma Metastatic to the Brain
J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3867 - 3871.
[Full Text]

Home page
 NEJMHome page
P. W. Ladenson, L. E. Braverman, E. L. Mazzaferri, F. Brucker-Davis, D. S. Cooper, J. R. Garber, F. E. Wondisford, T. F. Davies, L. J. DeGroot, G. H. Daniels, et al.
Comparison of Administration of Recombinant Human Thyrotropin with Withdrawal of Thyroid Hormone for Radioactive Iodine Scanning in Patients with Thyroid Carcinoma
N. Engl. J. Med., September 25, 1997; 337(13): 888 - 896.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. H. Emerson and R. Colzani
Epithelial Cell Thyroid Cancer and Thyroid Stimulating Hormone--When Less is More
J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 9 - 10.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1996 by The Endocrine Society